1.Cold haemagglutinin disease in systemic lupus erythematosus.
Krishnakumar NAIR ; Keechilat PAVITHRAN ; Joy PHILIP ; Mathew THOMAS ; Vasu GEETHA
Yonsei Medical Journal 1997;38(4):233-235
A 34-year-old lady presenting with features of cold agglutinin disease during the course of systemic lupus erythematosus is described. Cold antibody titer was very high (1 in 4096) with specificity for 'I' antigen. Even though she had poor prognostic factors like high titer of cold antibodies with low thermal amplitude, she responded well to prednisolone.
Adult
;
Anemia, Hemolytic, Autoimmune/immunology
;
Anemia, Hemolytic, Autoimmune/etiology*
;
Anemia, Hemolytic, Autoimmune/drug therapy
;
Antibodies/analysis
;
Case Report
;
Female
;
Human
;
Lupus Erythematosus, Systemic/complications*
;
Prednisolone/therapeutic use
;
Prognosis
3.A Case of Steroid Resistant Autoimmune Hemolytic Anemia in Ulcerative Colitis.
Hyun Jong CHOI ; Su Jin HONG ; Young Jee KIM ; Bong Min KO ; Moon Sung LEE ; Chan Sup SHIM ; Hyun Jung KIM ; Dae Sik HONG
The Korean Journal of Gastroenterology 2008;51(2):137-141
Autoimmunity is thought to play a central role in the pathogenesis of inflammatory bowel disease and associated extraintestinal manifestations. Autoimmune hemolytic anemia associated with ulcerative colitis is a rare occurrence. No more than 50 cases have been described in the international literatures, and only 2 cases reported in Korea. A 29-year-old woman who was diagnosed as ulcerative colitis two years ago was complicated with autoimmune hemolytic anemia, and did not respond to steroid therapy. Ultimately, total colectomy and splenectomy were carried out for the treatment of ulcerative colitis and hemolytic anemia. After the operation, anemia was resolved. We present the case with a review of literature.
Adult
;
Anemia, Hemolytic, Autoimmune/*diagnosis/drug therapy/etiology
;
Colectomy
;
Colitis, Ulcerative/complications/*diagnosis/pathology
;
Drug Resistance
;
Female
;
Humans
;
Splenectomy
;
Steroids/therapeutic use
4.Effect of beta-lactam antibiotics in drug-induced hemolysis.
Hui LI ; Li YANG ; Xi-Llin OUYANG ; Jing-Han LIU ; Quan-Li WANG
Journal of Experimental Hematology 2006;14(3):597-600
The study was purposed to evaluate synergistic effect of beta-lactam antibiotics in drug-induced hemolysis. The general information, including primary diseases, therapeutic drugs, infection pathogens in 6 patients with pulmonary infection and unknown reason anemia were integrated and analyzed. The leukocyte and reticulocyte counts, total bilirubin (TB), direct bilirubin (DB), fasting blood glucose (Glu in peripheral blood) were all determined by conventional method. At the same time, the erythrocyte direct antiglobulin test (DAT), complement fixation test (CFT), cell culture and smear examination were carried out. The antibodies in plasma were also detected by indirect antiglobulin test (IAT). The result showed that levels of WBC, TB, DB, Glu and reticulocyte in six patients treated with beta-lactam antibiotics were raised remarkably. DAT was strongly positive, but no RBC antibodies were detected in the plasma by IAT. The binding of red cells by monocytes or lymphocytes was great, and the hemolysis of red cells by alexin not appeared. After stopping above-mentioned beta-lactam antibiotic administration, patient's WBC, TB, DB, and Glu levels returned to normal values. Furthermore, DAT test result turned to negative. It is concluded that beta-lactam antibiotics lead to drug-induced hemolysis by non-specific adsorption of some proteins onto RBC surface, and their proteins may be considered as direct cause for this hemolysis.
Aged
;
Anemia, Hemolytic
;
chemically induced
;
etiology
;
Anti-Bacterial Agents
;
adverse effects
;
Female
;
Humans
;
Male
;
Middle Aged
;
Pneumonia, Bacterial
;
complications
;
drug therapy
;
beta-Lactams
;
adverse effects
5.A Case of Autoimmune Hemolytic Anemia Complicating Hematopoietic Cell Transplantation.
Hyojin CHAE ; Yonggoo KIM ; Myungshin KIM ; Jihyang LIM ; Kyungja HAN ; Seok Goo CHO ; Jong Wook LEE
The Korean Journal of Laboratory Medicine 2008;28(1):64-69
A 32-yr-old male diagnosed with myelodysplastic syndrome underwent an unmanipulated, unrelated, HLA matched, peripheral blood stem cell transplantation. The patient and donor were both blood type O, CcDEe. Twelve weeks post-transplantation, he developed acute autoimmune hemolytic anemia (AIHA). He was transfused multiple times with washed O red cells. High-dose steroid therapy was initiated and he underwent splenectomy; however, AIHA was refractory to therapy. The patient was further treated with combined treatment modalities including immunosuppressive therapy with mycophenolate mofetil and cyclosporine and three cycles of plasma exchange, and AIHA responded to treatment. This is the third case of AIHA complicating hematopoietic stem cell transplantation reported in Korea. Since AIHA is relatively common after hematopoietic stem cell transplantation, accurate and timely diagnosis of the disease and treatment strategies with multiple modalities are necessary.
Adult
;
Anemia, Hemolytic, Autoimmune/*diagnosis/drug therapy/etiology
;
Combined Modality Therapy
;
Cyclosporine/therapeutic use
;
Hematopoietic Stem Cell Transplantation/*adverse effects
;
Humans
;
Male
;
Mycophenolic Acid/analogs & derivatives/therapeutic use
;
Myelodysplastic Syndromes/complications/diagnosis/therapy
;
Plasma Exchange
6.Clinical and serological characterization of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.
Zhen YANG ; Bangzhao WU ; Youning ZHOU ; Wenjuan WANG ; Suning CHEN ; Aining SUN ; Depei WU ; Yang XU
Chinese Medical Journal 2014;127(7):1235-1238
BACKGROUNDAutoimmune hemolytic anemia (AIHA) is an uncommon complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) which has only been reported in a few cases. We here aimed to explore its mechanism.
METHODSWe retrospectively analyzed 296 patients who underwent allo-HSCT in our center from July 2010 to July 2012. Clinical manifestations were carefully reviewed and the response to currently available treatment approaches were evaluated. The survival and risk factors of AIHA patients after allo-HSCT were further analyzed.
RESULTSTwelve patients were diagnosed with AIHA at a median time of 100 days (15-720 days) after allo-HSCT. The incidence of AIHA after allo-HSCT was 4.1%. IgG antibody were detected in ten patients and IgM antibody in two patients. The two cold antibody AIHA patients had a better response to steroid corticoid only treatment and the ten warm antibody AIHA patients responded to corticosteroid treatment and adjustment of immunosuppressant therapy. Rituximab was shown to be effective for AIHA patients who failed conventional therapy. Survival analysis showed that the combination of AIHA in allo-HSCT patients hinted at poor survival. Cytomegalovirus (CMV) infection, graft-versus-host disease (GVHD) and histocompatibility leukocyte antigen (HLA) mismatch seemed to increase the risk of developing AIHA.
CONCLUSIONSPatients who develop AIHA after allo-HSCT have poor survival compared to non-AIHA patients. Possible risk factors of AIHA are CMV infection, GVHD, and HLA mismatch. Rituximab is likely to be the effective treatment choice for the refractory patients.
Adolescent ; Adrenal Cortex Hormones ; therapeutic use ; Adult ; Anemia, Hemolytic, Autoimmune ; diagnosis ; drug therapy ; etiology ; Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Child ; Child, Preschool ; Female ; Graft vs Host Disease ; diagnosis ; drug therapy ; etiology ; Hematopoietic Stem Cell Transplantation ; adverse effects ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Rituximab ; Transplantation, Homologous ; adverse effects ; Young Adult
7.An Imported Case of Severe Falciparum Malaria with Prolonged Hemolytic Anemia Clinically Mimicking a Coinfection with Babesiosis.
Young Ju NA ; Jong Yil CHAI ; Bong Kwang JUNG ; Hyun Jung LEE ; Ji Young SONG ; Ji Hye JE ; Ji Hye SEO ; Sung Hun PARK ; Ji Seon CHOI ; Min Ja KIM
The Korean Journal of Parasitology 2014;52(6):667-672
While imported falciparum malaria has been increasingly reported in recent years in Korea, clinicians have difficulties in making a clinical diagnosis as well as in having accessibility to effective anti-malarial agents. Here we describe an unusual case of imported falciparum malaria with severe hemolytic anemia lasting over 2 weeks, clinically mimicking a coinfection with babesiosis. A 48-year old Korean man was diagnosed with severe falciparum malaria in France after traveling to the Republic of Benin, West Africa. He received a 1-day course of intravenous artesunate and a 7-day course of Malarone (atovaquone/proguanil) with supportive hemodialysis. Coming back to Korea 5 days after discharge, he was readmitted due to recurrent fever, and further treated with Malarone for 3 days. Both the peripheral blood smears and PCR test were positive for Plasmodium falciparum. However, he had prolonged severe hemolytic anemia (Hb 5.6 g/dl). Therefore, 10 days after the hospitalization, Babesia was considered to be potentially coinfected. A 7-day course of Malarone and azithromycin was empirically started. He became afebrile within 3 days of this babesiosis treatment, and hemolytic anemia profiles began to improve at the completion of the treatment. He has remained stable since his discharge. Unexpectedly, the PCR assays failed to detect DNA of Babesia spp. from blood. In addition, during the retrospective review of the case, the artesunate-induced delayed hemolytic anemia was considered as an alternative cause of the unexplained hemolytic anemia.
Anemia, Hemolytic/chemically induced/*etiology/*pathology
;
Anti-Bacterial Agents/therapeutic use
;
Antimalarials/therapeutic use
;
Artemisinins/adverse effects/therapeutic use
;
Atovaquone/therapeutic use
;
Azithromycin/therapeutic use
;
Babesiosis/complications/*diagnosis/drug therapy/*pathology
;
Benin
;
Blood/parasitology
;
Coinfection/diagnosis/pathology
;
Drug Combinations
;
France
;
Humans
;
Korea
;
Malaria, Falciparum/complications/*diagnosis/drug therapy/*pathology
;
Male
;
Middle Aged
;
Plasmodium falciparum/*isolation & purification
;
Proguanil/therapeutic use
;
Travel
;
Treatment Outcome
8.Coinfection of hepatitis A virus genotype IA and IIIA complicated with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive immunoglobulin M anti-hepatitis E virus: a case report.
Hee Sup KIM ; Sook Hyang JEONG ; Je Hyuck JANG ; Hyung Joon MYUNG ; Jin Wook KIM ; Soo Mee BANG ; Sang Hoon SONG ; Haeryoung KIM ; Hae Sun YUN
The Korean Journal of Hepatology 2011;17(4):323-327
A 37-year-old male presented with fever and jaundice was diagnosed as hepatitis A complicated with progressive cholestasis and severe autoimmune hemolytic anemia. He was treated with high-dose prednisolone (1.5 mg/kg), and eventually recovered. His initial serum contained genotype IA hepatitis A virus (HAV), which was subsequently replaced by genotype IIIA HAV. Moreover, at the time of development of hemolytic anemia, he became positive for immunoglobulin M (IgM) anti-hepatitis E virus (HEV). We detected HAV antigens in the liver biopsy specimen, while we detected neither HEV antigen in the liver nor HEV RNA in his serum. This is the first report of hepatitis A coinfected with two different genotypes manifesting with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive IgM anti-HEV.
Adult
;
Anemia, Hemolytic, Autoimmune/*diagnosis/drug therapy/etiology
;
Anti-Inflammatory Agents/therapeutic use
;
Cholestasis/*diagnosis/drug therapy/pathology
;
Coinfection/*diagnosis
;
Genotype
;
Hepatitis A/complications/*diagnosis/genetics
;
Hepatitis E/complications/*diagnosis/genetics
;
Humans
;
Immunoglobulin M/blood
;
Liver/pathology/virology
;
Male
;
Prednisolone/therapeutic use
;
RNA, Viral/blood
9.Recent trends in the treatment of chronic hepatitis C.
Dae Won JUN ; Won Young TAK ; Si Hyun BAE ; Youn Jae LEE
The Korean Journal of Hepatology 2012;18(1):22-28
Pegylated interferon and ribavirin combination therapy is accepted as the standard antiviral treatment for chronic hepatitis C regardless of HCV genotype. This combination therapy achieves higher response rates than previous therapy, but, nevertheless, a large proportion of patients suffer from treatment failure or adverse events. Recent clinical studies of viral kinetics during antiviral treatment have led to the introduction of response-guided therapy, the concept of 'customized therapy depending on viral response', which focuses on modulation of the treatment period depending on the viral response to create a sustained viral response without unnecessary medication and costs. New upcoming direct-acting antivirals (DAAs) maximize response rate, and triple therapy including DAAs along with pegylated interferon and ribavirin combination therapy could soon be the standard therapy. In this article, we reviewed the factors affecting treatment, response guided treatment, retreatment after failure of standard treatment, management of adverse events during treatment, and new treatment options.
Anemia, Hemolytic/drug therapy/etiology
;
Antiviral Agents/adverse effects/*therapeutic use
;
Erythropoietin/therapeutic use
;
Hepatitis C, Chronic/*drug therapy
;
Humans
;
Individualized Medicine
;
Interferon-alpha/adverse effects/therapeutic use
;
Polyethylene Glycols/adverse effects/therapeutic use
;
Protease Inhibitors/therapeutic use
;
RNA, Viral/analysis
;
Recombinant Proteins/adverse effects/therapeutic use
;
Ribavirin/adverse effects/therapeutic use